

Ex-Head of Menarini Diabetes Unit Launches WaveSense Europe

Salem, New Hampshire, November 1, 2007 – The makers of the WaveSense line of blood glucose monitoring products (AgaMatrix), announced that Mr. Claudio Carboni, formerly of Menarini Diagnostics, has joined as Managing Director to launch WaveSense Europe, its European subsidiary. WaveSense Europe will distribute the company's high accuracy, WaveSense blood glucose meters and test strips in the European market both directly and through local partners.

Carboni has more than 15 years experience in the European blood glucose monitoring (BGM) market and nearly 10 years as Business Unit Director at Menarini Diagnostics. During his tenure, the company grew their BGM business 240% to over €160M in annual turnover and to an overall 10% market share in Europe, with leading market positions in Italy and Spain, making the diabetes business unit the largest in the company's diagnostic group. Carboni was also responsible for the business development, product launch, and marketing of Menarini's seven current BGM product lines, including GlucoMen™ and GlucoCard™. He also introduced the innovative GlucoDay™ continuous glucose monitoring system (CGMS). Prior to Menarini, he headed European marketing for MediSense, Inc., which was acquired by Abbott Diabetes Care (NYSE: ABT) in 1996.

"With a user base in Europe approaching 200,000, WaveSense has achieved a tremendous amount of presence in key markets such as Germany, Holland, Sweden, and Austria in an extremely short period of time. This is a tribute to how WaveSense's ability to deliver high accuracy resonates with a very discriminating market. I'm delighted to join the team and have a chance to take this to the next level," said Carboni.

The first products to be launched by WaveSense Europe will be the WaveSense Jazz™ and WaveSense Jazz Wireless™ products both of which have high accuracy and no calibration as key features. The features in Jazz were designed to help users achieve tighter control of their blood glucose levels. These include glycemic variability tracking, automatic mealtime tagging, positive feedback, and testing compliance tracking. In addition, the WaveSense Jazz Wireless can automatically and wirelessly download data to Zero-Click™, the company's data management software. For more details, see: <http://www.wavesense.info>.

John Alberico, President of AgaMatrix said “We are honored to welcome Claudio to our team and to support him as he leads the effort towards tremendous market growth of our WaveSense products in Europe. His experience at Menarini and MediSense, both proven European diagnostics leaders, speaks for itself. Given the importance of accuracy and quality in the very selective European blood glucose market, we feel that WaveSense products are uniquely positioned for rapid adoption to address important patient needs. ”

WaveSense Europe is currently considering a number of possible locations for its headquarters.

About AgaMatrix

AgaMatrix is a technology company headquartered in Salem, New Hampshire that develops and manufactures next generation blood glucose monitoring (BGM) products for the diabetes market. The Company’s proprietary WaveSense biosensor technologies (www.wavesense.info) enable significantly higher accuracy glucose sensing. Current products include a line of meter and strip systems and a blood glucose data management software system.

© 2002-2007 AgaMatrix, Inc. AgaMatrix; WaveSense; the WaveSense logo; WaveSense Jazz ; WaveSense Jazz Wireless; and Zero-Click are trademarks of AgaMatrix, Inc.

All trademarks are the properties of their respective owners.

This document is part of the WaveSense Site and all Content herein shall be covered by the Legal Notice found at: <http://www.wavesense.info/legal-statement>

Media Contact:

Anne Gvazdauskas

AgaMatrix, Inc.

Phone: +1 (603) 328 6081

Email: media@agamatrix.com